1 / 17

Abuse Deterrent Formulations

Abuse Deterrent Formulations. Syeda Saba Kareem, Pharm.D Pain and Palliative Care Specialty Resident H. Lee Moffitt Cancer Center & Research Institute Tampa, FL. Objectives. To review the mechanisms involved in opioid abuse To understand the mechanisms of abuse deterrent formulations

hao
Télécharger la présentation

Abuse Deterrent Formulations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abuse Deterrent Formulations Syeda Saba Kareem, Pharm.D Pain and Palliative Care Specialty Resident H. Lee Moffitt Cancer Center & Research Institute Tampa, FL

  2. Objectives • To review the mechanisms involved in opioid abuse • To understand the mechanisms of abuse deterrent formulations • To discuss formulations which are currently in different stages of development • Embeda® – • Alpharma Pharmaceuticals • Remoxy® – Pain Therapeutics/King Pharmaceuticals • Acurox® – Acura Pharmaceuticals • To discuss the timeline involved in product development

  3. Abuse Mechanism • Rapid Bioavailability • Crushing • Grinding/Chewing • Dissolving • Needle aspiration • Filtration and Solvent Extraction • Oral • Intravenous • Nasal Inhalation Lavine,G.  Abuse deterrence focus of upcoming opioid formulations. American Journal of Health-System Pharmacy. 65(5):381,385, March 1, 2008.

  4. Abuse Mechanism • Increased Concentration • Oral ingestion of excessive quantity • Polysubstance • Alcohol • Illicit substances Hahn C, McPherson M, Rubingh C. Pharmacotherapy for pain management: new treatment approaches. American Pharmacist Association. Sept 2008 http://apha.imirus.com/Mpowered/imirus.jsp?volume=ptpi08&issue=1&page=6

  5. Abuse Deterrent Mechanism • Physical Barrier • High viscosity gel capsule • Microencapsulation with insoluble coating • Pharmacological Barrier • Sequestered opioid antagonist • Aversive Agent Active ingredient Katz, N.P., et al. Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations. Clinical Journal of Pain,2007; 23(8):648-660

  6. Embeda® • Combination of extended-release morphine and sequestered naltrexone • ALO-01 (morphine sulfate extended release with sequestered naltrexone hydrochloride) capsules for the management of moderate to severe pain when a continuous, around the clock opioid analgesic is needed for an extended period of time, Alpharma Pharmaceutical LLC- NDA 22-32, Nov 2008

  7. Embeda® – Study 205 • Phase II, randomized, double blind study , N=32 • Subjective tool = Pharmacodynamic effects • Crushed/whole Embeda 120 mg < were lower than MSIR 120mg ALO-01 (morphine sulfate extended release with sequestered naltrexone hydrochloride) capsules for the management of moderate to severe pain when a continuous, around the clock opioid analgesic is needed for an extended period of time, Alpharma Pharmaceutical LLC- NDA 22-32, Nov 2008

  8. Embeda – Study 106 • Phase 1, randomized, double blind • IV morphine and IV naltrexone can decrease euphoric effects and lower abuse potiential ALO-01 (morphine sulfate extended release with sequestered naltrexone hydrochloride) capsules for the management of moderate to severe pain when a continuous, around the clock opioid analgesic is needed for an extended period of time, Alpharma Pharmaceutical LLC- NDA 22-321, Nov 2008

  9. Embeda – Study 205/106 • Abuse by swallowing crushed product • Snorting crushed product • Is naltrexone released and absorbed via nasal route? • Abuse by intravenous Morphine/Naltrexone • Injecting crushed/dissolved product • Is crushed product safe for IV route? • Nallani S. FDA Perspective of AL-01 Studies, FDA. Nov 21, 2008 • Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety & Risk Management Advisory Committee, FDA. Nov 14, 2008

  10. Remoxy® • Pain Therapeutics and King Pharmaceuticals – Orador™ Technology • Extended-release oxycodone in a high viscosity hard gelatin capsule • Remoxy XRT (oxycodone controlled-release) CII, Pain Therapeutics NDA22-324, Oct 2008

  11. Remoxy® – Study 821-CZ • Phase 1, randomized, crossover study (40mg) • Crushed Remoxy Vs. Crushed Oxycontin • Lower Cmax • Broad plateau = characteristic of extended release mechanism • Remoxy XRT (oxycodone controlled-release) CII, Pain Therapeutics NDA22-324, Oct 2008

  12. Remoxy® • FDA concluded that extended release characteristics are compromised upon manipulation • Ji P. Remoxy In Vivo Abuse Resistance Studies, FDA Nov 21, 2008

  13. Acurox ® • Acura Pharmaceuticals –Aversion® Technology • Aversion Technology; Acura Pharmaceuticals; Abuse deterrent products; Oct 2008 <http://www.acurapharm.com/Aversion.htm>

  14. Acurox® • Immediate release Oxycodone/subtherapeutic niacin • Gel forming polymer to reduce extraction • Mucosal irritating surfactant • Niacin (Vitamin B3) to induce flushing • Acurox Tablets; Acura Pharmaceuticals: Abuse deterrent products: Oct 2008 <http://www.acurapharm.com/Acurox%20Tablets.htm>

  15. Acurox® – Study 111 • Phase II, Single-Center, Randomized, Double-Blind • N = 30 • Assess the abuse liability/deterrence potential of Acurox® (8 X 5mg/30mg)Tablets vs oxycodone HCl 40mg alone • *Dislike/like scores (p = .033) • Treatment Enjoyment Assessment scores (p = .005) • LSD/dysphoria scores (p <.001) • Minimal difference in vital signs • Study AP-APF-111: A Phase II, Single-Center, Randomized, Double-Blind, Assessment of the Abuse Liability of Acurox® (oxycodone HCl and niacin) Tablets in Subjects with a History of Opioid Abuse; Acurox, Acura Pharmaceuticals <http://www.acurapharm.com/StudyAPADF111.htm>

  16. Product Timeline with FDA • Embeda® – Alpharma Pharmaceuticals • NDA – April 21, 2008 • NDA resubmitted – June 30, 2008 • 6 month priority review – Dec 30, 2008 • Remoxy® – Pain Therapeutics/King Pharmaceuticals • NDA – June 10, 2008 • 6 month priority review – Dec 10, 2008 • Acurox® – Acura Pharmaceuticals • Phase 3 completed • NDA expected to be submitted in 2008

  17. References • Lavine,G.  Abuse deterrence focus of upcoming opioid formulations. American Journal of Health-System Pharmacy. 65(5):381,385, March 1, 2008. • Katz, N.P., et al. Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations. Clinical Journal of Pain,2007; 23(8):648-660 • Hahn C, McPherson M, Rubingh C. Pharmacotherapy for pain management: new treatment approaches. American Pharmacist Association. Sept 2008 <http://apha.imirus.com/Mpowered/imirus.jsp?volume=ptpi08&issue=1&page=6> • ALO-01 (morphine sulfate extended release with sequestered naltrexone hydrochloride) capsules for the management of moderate to severe pain when a continuous, around the clock opioid analgesic is needed for an extended period of time, Alpharma Pharmaceutical LLC- NDA 22-321, Nov 2008 • Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety & Risk Management Advisory Committee, FDA. Nov 14, 2008 • Nallani S. FDA Perspective of AL-01 Studies, FDA Nov 21, 2008 • Remoxy XRT (oxycodone controlled-release) CII, Pain Therapeutics NDA22-324, Oct 2008 • Gilderman P, Butera D, Gilmore L, et al. Remoxy: A new opioid drug with effective analgesia and abuse-resistance.The Journal of Pain,7(4):2006 • Ji P. Remoxy In Vivo Abuse Resistance Studies, FDA Nov 21, 2008 • Aversion Technology; Acura Pharmaceuticals; Abuse deterrent products: Oct 2008 <http://www.acurapharm.com/Aversion.htm> • Acurox Tablets; Acura Pharmaceuticals: Abuse deterrent products: Oct 2008 <http://www.acurapharm.com/Acurox%20Tablets.htm> • Study AP-APF-111: A Phase II, Single-Center, Randomized, Double-Blind, Assessment of the Abuse Liability of Acurox® (oxycodone HCl and niacin) Tablets in Subjects with a History of Opioid Abuse; Acurox, Acura Pharmaceuticals <http://www.acurapharm.com/StudyAPADF111.htm> • Jasinski, R. Evaluation for flushing, safety and tolerability of niacin in combination with 40mg of oxycodone; Johns Hopkins University; Acura Pharmaceuticals • Werble C. NDA Sponsors Will Play Major Role In Policing Post-Market Controls. THE RPM November 24 2008

More Related